CS
Candriam SCA Portfolio holdings
AUM
$17.3B
1-Year Return
21.68%
This Quarter Return
+15.27%
1 Year Return
+21.68%
3 Year Return
+102.54%
5 Year Return
+176.54%
10 Year Return
+489.52%
AUM
$17.3B
AUM Growth
+$1.38B
(+8.6%)
Cap. Flow
-$439M
Cap. Flow
% of AUM
-2.53%
Top 10 Holdings %
Top 10 Hldgs %
32.07%
Holding
736
New
61
Increased
217
Reduced
342
Closed
55
Top Buys
| 1 |
Broadcom
AVGO
|
$108M |
| 2 |
Abbott
ABT
|
$55.5M |
| 3 |
Exelon
EXC
|
$45.5M |
| 4 |
Boston Scientific
BSX
|
$45.2M |
| 5 |
AbbVie
ABBV
|
$32.4M |
Top Sells
| 1 |
Tesla
TSLA
|
$84.8M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
$58.7M |
| 3 |
CrowdStrike
CRWD
|
$53.7M |
| 4 |
Merck
MRK
|
$39.1M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$38.2M |
Sector Composition
| 1 | Technology | 36.26% |
| 2 | Healthcare | 22.75% |
| 3 | Financials | 10.33% |
| 4 | Consumer Discretionary | 7.75% |
| 5 | Industrials | 7.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
CBRE Group
CBRE
$48B
| $22.5M | 0.13% |
160,654
-11,634
| -7% | -$1.63M |
|
152
GE Aerospace
GE
$299B
| $22.4M | 0.13% |
87,069
-58,521
| -40% | -$15.1M |
|
153
Twilio
TWLO
$16.3B
| $21.9M | 0.13% |
176,453
+1,881
| +1% | +$234K |
|
154
MetLife
MET
$54.4B
| $21.8M | 0.13% |
270,687
-95,048
| -26% | -$7.64M |
|
155
IBM
IBM
$231B
| $21.6M | 0.12% |
73,417
-44,012
| -37% | -$13M |
|
156
Blackrock
BLK
$172B
| $21.6M | 0.12% |
20,567
+8,337
| +68% | +$8.75M |
|
157
Quanta Services
PWR
$56.3B
| $21.3M | 0.12% |
56,358
+3,333
| +6% | +$1.26M |
|
158
Carlisle Companies
CSL
$16.5B
| $21M | 0.12% |
56,311
-20,965
| -27% | -$7.83M |
|
159
Intuit
INTU
$187B
| $20.6M | 0.12% |
26,183
+147
| +0.6% | +$116K |
|
160
Agnico Eagle Mines
AEM
$74.2B
| $20.5M | 0.12% |
172,718
+152,762
| +765% | +$18.2M |
|
161
Biogen
BIIB
$20.3B
| $20.5M | 0.12% |
163,315
-23,465
| -13% | -$2.95M |
|
|
VRNA
162
Verona Pharma
VRNA
$9.18B
| $20.5M | 0.12% |
216,400
-81,355
| -27% | -$7.69M |
|
163
Labcorp
LH
$22.8B
| $20.2M | 0.12% |
76,838
-262
| -0.3% | -$68.8K |
|
164
Manulife Financial
MFC
$52.3B
| $20M | 0.12% |
626,180
+73,553
| +13% | +$2.35M |
|
165
Crinetics Pharmaceuticals
CRNX
$3.21B
| $20M | 0.12% |
693,869
+204,958
| +42% | +$5.89M |
|
166
Ventas
VTR
$30.7B
| $19.9M | 0.11% |
315,400
+271,734
| +622% | +$17.2M |
|
167
CG Oncology
CGON
$2.41B
| $19.9M | 0.11% |
+763,580
| New | +$19.9M |
|
168
Rhythm Pharmaceuticals
RYTM
$6.87B
| $19.7M | 0.11% |
312,452
+20,983
| +7% | +$1.33M |
|
169
Texas Instruments
TXN
$170B
| $19.4M | 0.11% |
93,502
-94,157
| -50% | -$19.5M |
|
170
IDEAYA Biosciences
IDYA
$2.25B
| $19.2M | 0.11% |
914,400
-23,777
| -3% | -$500K |
|
171
Freeport-McMoran
FCX
$66.2B
| $19.2M | 0.11% |
442,965
+202,568
| +84% | +$8.78M |
|
172
KLA
KLAC
$116B
| $19.1M | 0.11% |
21,376
-7,822
| -27% | -$7.01M |
|
173
Ultragenyx Pharmaceutical
RARE
$3.02B
| $19.1M | 0.11% |
526,267
-201,750
| -28% | -$7.34M |
|
174
Sherwin-Williams
SHW
$91.4B
| $19.1M | 0.11% |
55,695
-915
| -2% | -$314K |
|
175
Citigroup
C
$179B
| $19.1M | 0.11% |
224,602
+5,827
| +3% | +$496K |
|